MENU

CSL’s shares sold off

Global biotherapy firm CSL (ASX: CSL) reported a strong set of financial results for the full year to June 2013 on Wednesday, however it’s been an unpleasant week for the company’s share price.

After opening Monday morning at $65.55, by the close of trade on Tuesday the stock had climbed to within a whisker of its all-time high of $68 in anticipation of the results. On Wednesday morning, with the results released to the market, the stock opened down 3% at $65.66 with that downtrend continuing through the rest of the week. By midday Friday the stock was trading at $63.37, down around 6.5% from the high reached on Tuesday.

To recap, these were the highlights from CSL’s results:

  • Sales rose 7% to US$5 billion
  • Earnings before interest and tax rose 17% to US$1,486 million
  • Net profit after tax rose 19% to US$1,216 million
  • Earnings per share rose 24% thanks to an on-going share buyback to US$2.44
  • Final dividend declared of US$0.52 cents per share, taking the full year dividend to US$1.02 per share, up 18% on the prior year.
  • The board announced it would consider a further share buyback

CSL’s management said the next 12 months would be tough and provided guidance for financial year (FY) 2014 of net profit after tax (NPAT) to grow by 10% with earnings per share (EPS) growth to exceed NPAT growth thanks to past and proposed management initiatives. Assuming this could lead to EPS growth in FY2014 of approximately 15%, an EPS figure of A$3.07 at current exchange rates could be expected. This places CSL on a forward price-to-earnings (PE) multiple of 20.7.

It’s been a mixed results season so far for investors in the healthcare sector. Shareholders in Cochlear (ASX: COH) were faced with a fall in earnings, however a boost from a new product release should see a stronger FY2014 result. While Resmed (ASX: RMD) continued its history of strong growth and surprised shareholders with a big increase in its dividend.

Foolish takeaway

Healthcare stocks have a history of selling at lofty valuations. Often this is justified but it does mean shareholders need to be extra vigilant. CSL shareholders currently need to be asking themselves if a PE multiple of over 20 times — given EPS growth of possibly 15% — is justified.

Looking for a less risky alternative? Interested in our #1 dividend-paying stock? Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading


Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!